Abbreviated Name

PCA3 Ref Set App: Zhang (2019)

Lead Investigator

Zhang, Hui L. — Johns Hopkins University School of Medicine

Coordinating Investigator

Feng, Ziding — Fred Hutchinson Cancer Center

Involved Investigators

• Feng, Ziding — Fred Hutchinson Cancer Center
• Zhang, Hui L. — Johns Hopkins University School of Medicine

Abstact

see Objectives

Aims

We propose the following two aims: 1. Determine the performance of using urinary glycoproteomics and mass spectrometry for the detection of aggressive prostate cancer. We will (a) validate 4 candidate glycoproteins to detect AG PCa in diagnostic biopsy in the NCI-EDRNs Urinary PCA3 Evaluation Trial: (b) with PCA3 trial samples further develop a glycoproteomic risk score for predicting AG Pca in diagnostic biopsy; (c) validate the utility of glycoproteins separately and in combination to predict prostate cancer with a higher tumor grade (i.e., Gleason 3+4 or greater) at radical prostatectomy with NCI-EDRN Tissue Upgrading cohort. 2. Develop and apply ELISA assays to verify the candidate glycoproteins as non-invasive urinary tests for detecting aggressive prostate cancer.

Analytic Method

Biomarkers

• ACP3
• DSC2
• PTGDS
• TMPRSS2

Data Collections

• No data collections available at this time for thie protocol

 Team Project

Protocol ID

460

Protocol Type

Reference Set

Field of Research

Glycomics

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of prostate

Phased Status

2